Remepy: Hybrid Drug Company Secures $15 Million
By Amit Chowdhry ● May 7, 2024
Remepy, a pioneer in hybrid drugs, announced that it closed a $10 million seed investment round, totaling $15 million when combined with earlier funding. This funding round was led by NFX and was joined by Vine Ventures, PsyMed Ventures, Supernode Ventures, and Firstime Ventures, while joining previous pre-seed lead investors TechAviv and Fresh.fund, Samsung Next, StageNext Fund, and 97212 Ventures.